128811-48-3

Basic information

• Product Name: (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE
• Synonyms: (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE;(R)-5-OXO-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER 2-METHYL ESTER;METHYL (R)-N-(TERT-BUTOXYCARBONYL)PYROGLUTAMATE;Boc-D-Pyroglutamic acid methyl ester;Boc-L-pyroglutamic acid methyl ester;(R)-1-Tert-butyl2-Methyl5-oxopyrrolidine-1,2-dicarboxylate;(R)-N-(tert-butoxycarbonyl)pyroglutaMate;1-Boc-5-oxo-D-proline Methyl ester
• CAS NO: 128811-48-3
• Molecular Formula: C₁₁H₁₇NO₅
• Molecular Weight: 243.26
• Mol File: 128811-48-3.mol

Chemical Properties

• Melting Point: 68-69℃
• Boiling Point: 361.637 °C at 760 mmHg
• Flash Point: 172.512 °C
• Appearance: /
• Density: 1.209
• Refractive Index: 1.506
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -4.28±0.40(Predicted)
• CAS DataBase Reference: (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE(128811-48-3)
• EPA Substance Registry System: (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE(128811-48-3)

Safety Data

• Hazardous Substances Data: 128811-48-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE is used as a key intermediate in the synthesis of (-)-Kaitocephalin, a non-selective ionotropic glutamate receptor antagonist. (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE is valuable for the development of drugs targeting neurological disorders and conditions related to glutamate receptor dysfunction.
In the synthesis of (-)-Kaitocephalin, (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE serves as a building block, providing the necessary chiral center and functional groups for the formation of the final product. Its unique structure allows for selective reactions and transformations, enabling the efficient synthesis of the desired compound with high enantiomeric purity.
Furthermore, the use of (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE in the pharmaceutical industry highlights its potential in the development of novel therapeutic agents. Its versatility and reactivity make it a valuable component in the synthesis of a wide range of bioactive molecules, contributing to the advancement of drug discovery and medicinal chemistry.

InChI:InChI=1/C11H17NO5/c1-10(2,3)17-9(16)12-7(13)5-6-11(12,4)8(14)15/h5-6H2,1-4H3,(H,14,15)/t11-/m1/s1

Upstream product

• 4042-36-8 D-pyrrolidone-5-carboxylic acid 
• 1538-75-6 2,2-dimethylpropanoic anhydride 
• 68766-96-1 ethyl (R)-2-pyrrolidone-5-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1564266-03-0 (R)-3-hydroxyadamantylglycine-D-trans-4,5-methanoprolinenitrile 
• 1564266-00-7 (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile 
• 1564265-95-7 (R)-3-hydroxyadamantylglycine-D-cis-4,5-methanoprolinenitrile 
• 1564265-94-6 (S)-3-hydroxyadamantylglycine-D-cis-4,5-methanoprolinenitrile 
• 1266231-39-3 1-[(1R,3R,5R)-2-azabicyclo[3.1.0]hex-3-yl]-N-benzylmethanamine 
• 1452400-41-7 methyl (1aR,4R,6aR,7aR)-5-benzyloctahydro-1H-cyclopropa[4,5] pyrrolo[1,2-a]pyrazine-4-carboxylate 
• 1266231-40-6 methyl (1aR,4S,6aR,7aR)-5-benzyloctahydro-1H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-4-carboxylate 
• 1266231-37-1 tert-butyl (1R,3R,5R)-3-[(benzylamino)methyl]-2-azabicyclo[3.1.0]hexane-2-carboxylate 
• 1266231-48-4 tert-butyl [(1S)-2-{[(1S)-1-cyclohexyl-2-{(1aR,4S,6aR,7aR)-4-[(4R)-3,4-dihydro-2H-chromen-4-ylcarbamoyl]octahydro-5H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazin-5-yl}-2-oxoethyl]amino}-1-methyl-2-oxoethyl]methylcarbamate 
• 1143524-77-9 C₁₉H₂₄FNO₅ 
• 1356351-76-2 (2R,4S)-1-(2-(1H-1,2,3-triazol-1-yl)acetyl)-4-(4-fluorobenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide 
• 1229439-70-6 C₁₇H₂₂FNO₄ 
• 575452-35-6 (+)-1-(tert-butyl) 2-ethyl (2R)-pyrrolidine-1,2-dicarboxylate 
• 937814-59-0 (R)-2-tert-butoxycarbonylamino-5-(4-chlorophenyl)-5-oxopentanoic acid ethyl ester 

Relevant articles and documents

CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP4 subtype of PGE2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.

Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin

All eight stereoisomers of saxagliptin have been synthesized and evaluated for their inhibitory activity against DPP-IV. It was unambiguously confirmed that the configuration of saxagliptin was critical to potent inhibition of DPP-IV. Docking study was performed to elucidate the configuration-activity relationship of saxagliptin stereoisomers. Tyr662 and Tyr470 have been suggested as the key residues of DPP-IV interacting with the inhibitors. This work provides valuable information for further inhibitor design against DPP-IV.

CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP 4 sub type of PGE2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and theiruse as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.

Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists

A series of subtype selective sphingosine 1-phosphate receptor 1 (S1P 1) antagonists are disclosed. Our high-throughput screening campaign revealed hit 1 for which an increase in potency and mouse oral exposure was achieved with minor modifications to the chemical scaffold. In vivo efficacy revealed that at high doses compounds 12 and 15 inhibited tumor growth. Further optimization of our lead series led to the discovery of proline derivatives 37 (XL541) and 38 which had similar efficacy as our first generation analogues at significantly lower doses. Analogue 37 displayed excellent pharmacokinetics and oral exposure in multiple species.

PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE

The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

Heterocyclic Compound

The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention shows a strong IAP antagonistic activity.

Prodrug of cinnamide compound

The present invention provides a most suitable prodrug of a cinnamide compound. The prodrug is represented by Formula (I) wherein Ra and Rb each denote a C1-6 alkyl group or the like; Xa denotes a methoxy group or a fluorine atom; Y denotes a phosphono group or the like; and A denotes a cyclic lactam derivative.

(d)-2-tert-Butoxycarbonylamino-5,5-difluoro-5-phenyl-pentanoic acid: Synthesis and incorporation into the growth hormone secretagogues

The first enantioselective synthesis of (d)-2-tert-butoxycarbonylamino-5,5-difluoro-5-phenyl-pentanoic acid 3 was achieved. The incorporation of the titled compound into growth hormone secretagogue (GHS) compounds resulted in new analogs 10 and 16, both o

TWO CYCLIC OXOMORPHORIN DERIVATIVES

The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.

THIOPHENE DERIVATIVES AS PPAR AGONISTS I

The invention discloses compounds of formula (I); wherein: R is a carboxylic acid or a derivative thereof; R1 is alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylthio, halo or trihalomethyl; R2 is aryl, heteroaryl, arylalkyl or heteroarylalkyl; R3 is H or F; and L is a linking group comprising a chain of from 2 to 8 atoms linking R and the carbonyl group (A); and pharmaceutically acceptable derivatives thereof, useful for treating disorders mediated by peroxisome-proliferator-activated receptor (PPAR) subtype δ (PPARδ). The compounds of the invention are therefore useful in the treatment of metabolic syndrome, obesity, type-II diabetes, dyslipidemia, wound healing, inflammation, neurodegenerative disorders and multiple sclerosis.